AI-CRIC Study: Understanding Kidney and Heart Disease in American Indians
This observational study, called the American Indian Chronic Renal Insufficiency Cohort Study (AI-CRIC), aims to better understand chronic kidney disease (CKD) and heart disease in American Indian communities. Researchers want to identify unique risk factors for these conditions and compare how they progress in American Indians versus other populations. You might be eligible if you are between 21 and 80 years old and have certain levels of kidney function (eGFR of 61-80 with microalbuminuria, or eGFR of 60 or less). The study will look at how your kidney function changes over 5 years. The current status of this study is unclear.
- Study design
- This is an observational study planning to enroll 500 participants. It does not involve a specific intervention or drug.
- What's involved
- You will have an initial clinic visit lasting 1-2 hours, which includes measurements, blood draws, urine collection, and questionnaires. You will also have phone calls six months after your first visit and annual follow-up visits.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed annually, and the primary endpoint for kidney function change is measured at 5 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
American Indian Chronic Renal Insufficiency Cohort Study (AI-CRIC Study)
At a glance
Conditions
Where it's being run
3 sites across 2 statesStudy leadership
- Mark L Unruh, MD · PRINCIPAL_INVESTIGATOR · University of New Mexico
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- Slope of the GFR5 years
Primary outcomes regarding Cardio vascular disease will focus on clinical events indicative of ischemic heart disease, CHF, stroke, and peripheral vascular disease supplemented by radiographic evidence of progressive CVD.